OncoMatch/Clinical Trials/NCT06305910
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
Is NCT06305910 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Treatment with CD200AR-L for diffuse midline glioma, h3 k27m-mutant.
Treatment: Treatment with CD200AR-L — This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Biomarker criteria
Required: H3C2 K27M
documented H3K27M alteration (based on IHC or DNA sequencing performed in a CLIA-certified laboratory)
Prior therapy
Must have received: radiation therapy — at diagnosis (for recurrent HGG)
Recurrent HGG must have received standard of care radiation at diagnosis
Lab requirements
Blood counts
absolute neutrophil (segmented and bands) count (anc) ≥1.0 x 10e9/l, platelets ≥75 x 10e9/l; hemoglobin ≥8 g/dl
Kidney function
normal serum creatinine for age or creatinine clearance >60 ml/min/1.73 me2
Liver function
bilirubin ≤1.3 mg/dl and sgpt (alt) ≤2.5 x upper limit of normal (uln) for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify